Abstract The fully human anti-lipopolysaccharide (LPS) immunoglobulin M (IgM) monoclonal antibody panobacumab was developed as an adjunctive immunotherapy for the treatment of O11 serotype Pseudomonas aeruginosa infections. We evaluated the potential clinical efficacy of panobacumab in the treatment of nosocomial pneumonia. We performed a post-hoc analysis of a multicenter phase IIa trial (NCT00851435) designed to prospectively evaluate the safety and pharmacokinetics of panobacumab. Patients treated with panobacumab (n=17), including 13 patients receiving the full treatment (three doses of 1.2 mg/kg), were compared to 14 patients who did not receive the antibody. Overall, the 17 patients receiving panobacumab were more ill. These preliminary results suggest that passive immunotherapy targeting LPS may be a complementary strategy for the treatment of nosocomial O11 P. aeruginosa pneumonia.
Introduction
Pseudomonas aeruginosa is a recalcitrant, opportunistic Gram-negative bacteria responsible for most nosocomial infections of critically ill patients [1] [2] [3] . The development of multidrug resistance makes the treatment of infections caused by this pathogen challenging [4, 5] and accounts for the persistently high mortality rates observed in recent surveys [6, 7] , despite aggressive supportive management [8, 9] . The number of new antimicrobials under clinical development remains extremely limited, and their introduction to the market is disappointingly slow [10] , highlighting the urgency for innovative approaches to be developed for the management of multidrug-resistant infections [11, 12] .
Adjunctive passive immunotherapy specifically targeted at microbial products could be a promising strategy in overcoming this problem. Historically, passive immunotherapy using anti-sera was successfully carried out before the antibiotic era for the management of devastating infectious diseases, such as rabies and diphtheria [13] . The administration of intravenous immunoglobulins as prophylaxis or as combination therapy with antibiotics has shown promising results in treating sepsis [14, 15] . The development of monoclonal antibodies (MAbs) has improved antibody-based therapies by targeting specific virulence factors on respective pathogens. However, adjunctive immunotherapy targeted at host response mediators has, so far, failed [16] . Therapies combining antimicrobials with MAbs targeted at bacterial targets may potentially result in a more rapid resolution of infections, resulting in reductions in sepsis-related morbidity and mortality [17] .
The membrane-bound virulence factor lipopolysaccharide (LPS), expressed by all Gram-negative bacteria like P. aeruginosa, elicits an immunoglobulin M (IgM)-mediated antibody response that takes several days to fully develop, and this delay may increase the risk of death in severe infections [18] . Human monoclonal antibodies directed against P. aeruginosa LPS have demonstrated protection in various settings [19] [20] [21] . Panobacumab is a fully human monoclonal antibody of the IgM/κ isotype directed against the LPS Opolysaccharide moiety of P. aeruginosa O11 [22, 23] . P. aeruginosa international antigenic scheme serotypes O11 and O6 have been reported to be the most prevalent serotypes among epidemiological studies [24, 25] . Strains exhibiting exotoxin U, a potential virulence factor, were frequently serotyped as O11 [25, 26] . In an experimental model of pneumonia, serotype O11 was found to be associated with increased lung injury [27] . These epidemiological data were confirmed by a recent retrospective cohort study on 123 patients with nosocomial P. aeruginosa pneumonia, in which O6 (29 %) and O11 (23 %) were the most prevalent serotypes [28] . In this study, serotype O11 was associated with increased persisting pneumonia and decreased clinical resolution compared to other serotypes. Preliminary data from an open phase IIa study demonstrated the safety of panobacumab in critically ill patients presenting with P. aeruginosa O11 nosocomial pneumonia [29] . We performed a post-hoc analysis of this study to evaluate the potential clinical efficacy of panobacumab in the treatment of P. aeruginosa O11 nosocomial pneumonia. The 17 patients that received panobacumab were compared to a group of 14 patients screened in the study that did not receive immunotherapy.
Patients and methods

Study population
We performed a post-hoc analysis of the multicenter, open pilot phase IIa clinical trial (NCT00851435) which prospectively evaluated the safety and pharmacokinetics of at least one dose of 1.2 mg/kg panobacumab, a fully human monoclonal anti-LPS IgM, given every 72 h in 17 patients with microbiologically documented [bronchoalveolar lavage (BAL), mini-BAL] serotype O11 P. aeruginosa pneumonia [29] . Definitions and detailed inclusion/exclusion criteria are described elsewhere [29] . These patients (intent-to-treat group) and those receiving the full three-dose treatment (per-protocol group) were compared to a group consisting of patients who fulfilled all the inclusion and exclusion criteria of the phase IIa study but who could not receive panobacumab (not treated with panobacumab group) ( Fig. 1 ) for the following reasons: (i) treatment refusal (n=3); (ii) physicians refused to give the treatment (n=3); (iii) patients were screened after the end of the trial (n=3); (iv) delayed serotyping results (n=2); or (iv) unknown reasons (n=3).
Data collection
In addition to demographics (age, gender), the general condition of the patients was evaluated using the Acute Physiology and Chronic Health Evaluation II (APACHE II) score system [30] . Organ dysfunction was evaluated using the Sequential Organ Failure Assessment (SOFA) score [31] . The severity of pneumonia was assessed using the Clinical Pulmonary Infection Score (CPIS) [32] .
Clinical endpoints
The clinical endpoints were as follows: (i) survival defined as survival by day 30; (ii) clinical resolution was defined as no persisting symptoms or complications attributable to the pneumonia with a return to normal values of all four of the following: core body temperature (<38.3°C), peripheral blood leucocyte count (<10 × 10 clinical signs and a diagnostic culture; (v) death was scored as a non-resolved infection.
Statistical analysis
Statistical analyses compared patients that received at least one dose or three doses of panobacumab to control patients. Continuous variables are presented as median [range, interquartile range (IQR)]. The characteristics of patients and clinical outcomes were compared using Fisher's exact test and the Wilcoxon rank-sum test, as indicated. Time to clinical resolution was analyzed using the Kaplan-Meier survival model. All tests were two-tailed, and statistical significance was established at p-values <0.05.
Results
Demographics and severity of nosocomial pneumonia
The phase IIa clinical trial designed to test the safety, pharmacokinetics, and potential efficacy of panobacumab adjunctive therapy screened 146 P. aeruginosa microbiologically documented nosocomial pneumonia cases. Thirty-one patients were diagnosed with O11 serotype P. aeruginosa infections. Among these, 17 fulfilled the inclusion criteria (intent-to-treat group): four patients received only one dose and 13 patients received the planned three doses of panobacumab (perprotocol group). Fourteen patients suffering from nosocomial pneumonia caused by P. aeruginosa O11 but who did not receive panobacumab were used as untreated controls (Fig. 1) .
The patient characteristics are summarized in The severity of pneumonia and the characteristics of antibiotic treatment were comparable among treated and untreated patients.
Outcome
The mortality rates were not statistically significant between groups. A total of six patients died, including three receiving only one dose of panobacumab. One patient died 3 days after the first doses from a gastrointestinal hemorrhage before receiving the second dose. Adjunctive treatment was stopped in a different patient after the first dose following worsening of preexisting cholestasis, who also presented with neutropenia and gastrointestinal bleeding (he died on day 17 from multiple organ failure). In a third patient, cardiac arrest followed by increased prothrombin time (possibly related to panobacumab treatment) precluded further panobacumab administration. This patient died on day 17 after a second cardiac arrest. Three patients who did not receive adjunctive treatment died on days 8, 10, and 16, respectively, from colitis-related septic shock, pneumonia-related multiple organ failure, and indeterminate causes, respectively.
Effect of adjunctive passive immunotherapy
When untreated patients were compared to patients that received≥1 dose of panobacumab (intent-to-treat group), there was no significant differences in clinical outcome, with a shorter time to clinical resolution of pneumonia and more disease-free days (Table 2 ). Differences were statistically significant when untreated patients were compared to patients that received the full planned treatment (three doses of panobacumab). Specifically, time to clinical resolution was 8.0 days (IQR: 7-12) versus 18.5 days (IQR: 8-30) (p=0.004), clinical resolution of (Fig. 2) . Two out of 13 patients receiving three doses of panobacumab versus 1/14 untreated patients developed recurrent pneumonia within 30 days (not statistically different).
Discussion
This manuscript describes a proof-of-concept analysis describing the administration of passive adjunctive immunotherapy of a human monoclonal antibody that specifically targeted Differences were statistically significant only between patients that received three doses of panobacumab. In these patients, an 85 % success rate and a more rapid clinical resolution was achieved, despite these patients presenting with more severe infections and underlying conditions.
Three patients that received only one dose of panobacumab adjunctive immunotherapy died. One died early from septic shock related to the infection and two patients that were excluded by the independent phase IIa panobacumab clinical trial safety committee died later. This may be viewed as a limitation, but it should be pointed out that the full effect of adjunctive immunotherapy targeted at a virulence factor may not be achieved immediately and that repetitive doses may be required to achieve a clinical effect.
These results are consistent with previous in vitro and in vivo data obtained with panobacumab. The diffusion of panobacumab from blood into the alveolar spaces may have contributed to its efficacy [29] . Moreover, observed relapses at day 30 may be explained by the disappearance of panobacumab from the blood [29] at this time.
Conclusions regarding the clinical efficacy of panobacumab in the treatment of nosocomial P. aeruginosa O11 infections should be made with caution, since this post-hoc analysis consisted of a limited number of patients. Nevertheless, such preliminary results are encouraging and may justify a large prospective randomized clinical trial in critically ill patients presenting with P. aeruginosa nosocomial infections.
In summary, these preliminary results suggested that the full course of panobacumab adjunctive immunotherapy (three doses) targeting serotype-specific LPS of P. aeruginosa O11 may have improved the clinical outcome of patients presenting with nosocomial pneumonia.
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